Tao et al. specifically investigated a cohort of EGFR-mutant NSCLC patients with multiple brain metastasis and thereby demonstrated that EGFR-TKI plus bevacizumab, compared to EGFR-TKI monotherapy, showed improvement of both intracranial and systemic tumor responses30. This evidence concerns the gene EGFR and non-small cell lung carcinoma.